These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 31992459)

  • 21. Bioequivalence of fixed-dose combinations of dapagliflozin and metformin with single-component tablets in healthy subjects and the effect of food on bioavailability.
    de Bruin TW; Reele S; Hamer-Maansson JE; Parikh S; Tang W
    Clin Pharmacol Drug Dev; 2016 Mar; 5(2):118-30. PubMed ID: 27138025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers.
    Macha S; Mattheus M; Pinnetti S; Broedl UC; Woerle HJ
    Clin Ther; 2015 Jul; 37(7):1503-16. PubMed ID: 26051874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin.
    Kasichayanula S; Chang M; Liu X; Shyu WC; Griffen SC; LaCreta FP; Boulton DW
    Adv Ther; 2012 Feb; 29(2):163-77. PubMed ID: 22271159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of pharmacokinetic interactions between lobeglitazone, empagliflozin, and metformin in healthy subjects.
    Kim H; Kim CO; Park H; Park MS; Kim D; Hong T; Shin Y; Jin BH
    Transl Clin Pharmacol; 2023 Mar; 31(1):59-68. PubMed ID: 37034122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers.
    Brand T; Macha S; Mattheus M; Pinnetti S; Woerle HJ
    Adv Ther; 2012 Oct; 29(10):889-99. PubMed ID: 23054692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dapagliflozin twice daily or once daily: effect on pharmacokinetics and urinary glucose excretion in healthy subjects.
    Tang W; Reele S; Hamer-Maansson JE; Parikh S; de Bruin TW
    Diabetes Obes Metab; 2015 Apr; 17(4):423-5. PubMed ID: 25511685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin.
    Jung JA; Lee SY; Kim TE; Kim JR; Kim C; Huh W; Ko JW
    Drug Des Devel Ther; 2015; 9():737-43. PubMed ID: 25767371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus.
    Tirucherai GS; LaCreta F; Ismat FA; Tang W; Boulton DW
    Diabetes Obes Metab; 2016 Jul; 18(7):678-84. PubMed ID: 27291448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic Interactions Between Gemigliptin and Metformin, and Potential Differences in the Pharmacokinetic Profile of Gemigliptin Between the Mexican and Korean Populations: A Randomized, Open-label Study in Healthy Mexican Volunteers.
    Conde-Carmona I; García-Medina S; Jiménez-Vargas JM; Martínez-Muñoz A; Lee SH
    Clin Ther; 2018 Oct; 40(10):1729-1740. PubMed ID: 30249366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers.
    Macha S; Sennewald R; Rose P; Schoene K; Pinnetti S; Woerle HJ; Broedl UC
    Clin Ther; 2013 Mar; 35(3):226-35. PubMed ID: 23497760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of rosuvastatin/olmesartan fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects.
    Son H; Roh H; Lee D; Chang H; Kim J; Yun C; Park K
    Clin Ther; 2013 Jul; 35(7):915-22. PubMed ID: 23810276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.
    Kasahara N; Fukase H; Ohba Y; Saito T; Miyata K; Iida S; Takano Y; Ikeda S; Harigai M; Terao K
    Drug Res (Stuttg); 2016 Feb; 66(2):74-81. PubMed ID: 26158794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Hepatic Impairment on the Pharmacokinetic Profile and Safety of Lobeglitazone.
    Park J; Kim CO; Oh ES; Lee JI; Kim JK; Ahn SH; Kim DY; Kim SU; Kim BK; Chung YE; Kim SM; Park MS
    Clin Pharmacol Drug Dev; 2022 May; 11(5):576-584. PubMed ID: 35255191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects.
    Smulders RA; Zhang W; Veltkamp SA; van Dijk J; Krauwinkel WJ; Keirns J; Kadokura T
    Diabetes Obes Metab; 2012 Oct; 14(10):937-43. PubMed ID: 22587345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study.
    Sha S; Polidori D; Farrell K; Ghosh A; Natarajan J; Vaccaro N; Pinheiro J; Rothenberg P; Plum-Mörschel L
    Diabetes Obes Metab; 2015 Feb; 17(2):188-97. PubMed ID: 25421015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complementary effects of dapagliflozin and lobeglitazone on metabolism in a diet-induced obese mouse model.
    Lee YK; Oh TJ; Lee JI; Choi BY; Cho HC; Jang HC; Choi SH
    Eur J Pharmacol; 2023 Oct; 957():175946. PubMed ID: 37541370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the efficacy of a combination of dapagliflozin and lobeglitazone on glucose concentrations and body fat in patients with type 2 diabetes: Location-F study.
    Choe HJ; Oh HR; Bu D; An N; Scherer PE; An Z; Lim S
    Diabetes Obes Metab; 2024 Mar; 26(3):1114-1119. PubMed ID: 38073421
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus.
    Tang W; Leil TA; Johnsson E; Boulton DW; LaCreta F
    Diabetes Obes Metab; 2016 Mar; 18(3):236-40. PubMed ID: 26510924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study.
    Kasichayanula S; Liu X; Zhang W; Pfister M; LaCreta FP; Boulton DW
    Clin Ther; 2011 Nov; 33(11):1798-808. PubMed ID: 22030444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioequivalence and food effect of heat-stressed and non-heat-stressed dapagliflozin 2.5- and 10-mg tablets.
    LaCreta F; Griffen SC; Liu X; Smith C; Hines C; Volk K; Tejwani R; Boulton DW
    Int J Pharm; 2016 Sep; 511(1):288-295. PubMed ID: 27418571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.